Sign In
Buy KALA
$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
KALA BIO Announces Reverse Stock Split
09:00am, Thursday, 07'th May 2026
ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common st
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
07:00am, Tuesday, 21'st Apr 2026
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
KALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Survey
02:02am, Monday, 06'th Apr 2026
Celularity (NASDAQ: CELU - Get Free Report) and KALA BIO (NASDAQ: KALA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses ba
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
06:45am, Wednesday, 01'st Apr 2026
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, develop
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
08:45am, Monday, 30'th Mar 2026
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Genera
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
08:31am, Monday, 30'th Mar 2026
The company confirmed that BIRA is now live in client-controlled environments, marking its entry into revenue-generating AI infrastructure.
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of “Hold” from Analysts
04:32am, Friday, 27'th Mar 2026
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are covering the firm, MarketBeat.com reports. One equities research anal
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto,
Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA) Toronto, Ontari
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
06:30am, Wednesday, 11'th Mar 2026
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to
Stock Trend Capital Provides Younet AI Investment Update
06:20am, Monday, 09'th Mar 2026
Younet AI Partners with KALA BIO to Deploy AI Infrastructure for the Biotech Industry Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - Stock Trend Capital Inc. (CSE: STCQ) (FSE: P0G) (O
KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model
01:12pm, Wednesday, 04'th Mar 2026
KALA BIO (KALA) shares rose after unveiling a strategic initiative to build an on-premises AI infrastructure platform for biotech.
ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”), a clinical-stage biopharmaceutical company, today announced a strategic initiative
KALA BIO, Inc. (NASDAQ:KALA) Receives $20.38 Average Price Target from Brokerages
04:08am, Sunday, 08'th Feb 2026
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) has been given an average recommendation of "Hold" by the six ratings firms that are presently covering the firm, MarketBeat.com reports. One research a
